InflaRx shares surge 63.41% after-hours after positive INF904 Phase 2a data in HS and CSU drive investor optimism.

InflaRx surged 63.41% in after-hours trading following the release of positive Phase 2a clinical trial data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study demonstrated INF904’s rapid and sustained efficacy, including significant reductions in lesions, pain, and inflammatory markers, with no serious adverse events. These results position INF904 as a potential best-in-class oral C5aR inhibitor with a $1 billion addressable market. The company plans to advance to Phase 2b trials in HS by 2026 and expand development in CSU, while engaging collaborators to accelerate progress. The data, coupled with a webcast and upcoming Q3 financial results, fueled investor optimism, driving the sharp after-hours increase.